Severe drug-associated colitis with Crohn’s features in setting of ixekizumab therapy for chronic plaque psoriasis
| Autor: | Stephanie Reid, Julia Trahey, John Fardy, Xin Mu |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Drug
Male medicine.medical_specialty Drug-associated colitis media_common.quotation_subject Ixekizumab Case Report RC799-869 Disease Antibodies Monoclonal Humanized Inflammatory bowel disease Severity of Illness Index Crohn Disease Psoriasis Internal medicine medicine Humans Colitis media_common Plaque psoriasis business.industry Gastroenterology General Medicine Diseases of the digestive system. Gastroenterology Hepatology Middle Aged medicine.disease Treatment Outcome Pharmaceutical Preparations Dermatologic Agents business |
| Zdroj: | BMC Gastroenterology BMC Gastroenterology, Vol 21, Iss 1, Pp 1-4 (2021) |
| ISSN: | 1471-230X |
| Popis: | Background Ixekizumab is monoclonal antibody targeted against interleukin-17 (IL-17) and has been approved for use in chronic plaque psoriasis. Despite its efficacy in treating psoriasis, concerns have been raised regarding Ixekizumab’s potential to induce and exacerbate inflammatory bowel disease (IBD). Case presentation Here we report the new onset of severe drug-associated colitis with surgical complications in a 45-year-old male patient who was receiving Ixekizumab therapy for chronic plaque psoriasis. Review of the patient’s colonic pathology demonstrated acute inflammatory changes with features of Crohn’s disease. The patient remained disease-free 9-months following his hospitalization and cessation of Ixekizumab. Conclusions This case raises suspicion for an association between Ixekizumab and IBD and calls on clinicians to have heightened awareness of potential risks before prescribing anti-IL-17 agents. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink